降低脂蛋白a药物在心血管疾病治疗中的研究进展  

Research Progress of Lipoprotein(a)Lowering Drugs in Treatment of Cardiovascular Diseases

作　　者：梁好 朱业 LIANG Hao;ZHU Ye(School of Clinical Medicine,Yangzhou University,Yangzhou 225001,China;Department of Cardiovascular Medicine,Northern Jiangsu People′s Hospital,Yangzhou 225001,China)

机构地区：[1]扬州大学临床医学院,江苏扬州225001 [2]苏北人民医院心血管内科,江苏扬州225001

出　　处：《医学综述》2024年第16期2019-2024,共6页Medical Recapitulate

基　　金：国家自然科学基金(81800250);中国博士后科学基金(2022M711417);江苏省中医药科技发展计划项目(MS2023137);扬州市科技计划项目(YZ2023096)。

摘　　要：脂蛋白a[Lp(a)]是一种特殊的脂蛋白颗粒,由一种低密度脂蛋白样颗粒和载脂蛋白A结合而成。Lp(a)水平升高已被证实为心血管疾病的独立危险因素,也被作为引起低密度脂蛋白胆固醇升高的风险因子。然而近年来关于降低Lp(a)的治疗仍在不断研究中,脂蛋白单采术是降低Lp(a)最有效的方法,但因其操作复杂尚未广泛使用。目前很多药物(如他汀类药物、前角蛋白转化酶枯草溶菌素9抑制剂、干扰小RNA分子药物以及新型口服药)降低Lp(a)的疗效及副作用尚不清楚,未来需对相关药物进一步完善以及开发新型更有效、更便捷的药物。Lipoprotein(a)[Lp(a)]is a special kind of lipoprotein particle,which is formed by combining a low-density lipoprotein-like particle with apolipoprotein A.Elevated Lp(a)levels have been established as an independent risk factor for cardiovascular disease and are also recognized as risk factors that can cause elevated low-density lipoprotein cholesterol.However,in recent years,the treatment that can reduce Lp(a)is still under continuous research,and lipoprotein apheresis is the most effective method to reduce Lp(a)at present,but it has not been widely used due to its complex operation.The efficacy and side effects of many drugs(such as statins,prokeratin convertase subtilisin 9 inhibitor,small RNA interfering drugs,and new oral drugs)in reducing Lp(a)are not clear.In the future,further improvement of related drugs and the development of new,more effective and convenient drugs are needed.

关 键 词：心血管疾病 脂蛋白A 药物治疗 

分 类 号：R541[医药卫生—心血管疾病]